Zemcelpro®: A New Hope for Patients with High-Risk Blood Cancers Revealed at EBMT 2026 ExCellThera's Zemcelpro® demonstrates remarkable survival rates for high-risk blood cancer patients, showcasing vital findings set for presentation at EBMT 2026.

Zemcelpro®: A New Hope for Patients with High-Risk Blood Cancers Revealed at EBMT 2026 #Canada #Montreal #ExCellThera #Zemcelpro® #Cordex_Biologics

Promising Outcomes for High-Risk Blood Cancer Therapy from ExCellThera Set to be Revealed at EBMT 2026 ExCellThera Inc. reveals encouraging results from Zemcelpro® (dorocubicel) in treating high-risk blood cancers, poised for presentation at EBMT 2026.

Promising Outcomes for High-Risk Blood Cancer Therapy from ExCellThera Set to be Revealed at EBMT 2026 #Canada #Montreal #Zemcelpro #ExCellThera #dorocubicel

✨ #ExCellThera 🇨🇦 annonce que #Zemcelpro ( #CAR_Tcell ✂️ #UM171 💉) a obtenu l’autorisation de l' #UE 🇪🇺 en tant que 1ère & unique #ThérapieCellulaire 🧬 pour les patients atteints de #CancersDuSang 🩸 ne disposant pas d’un donneur approprié de #CellulesSouches 🩸
excellthera.com/fr/news/zemc...

Zemcelpro® Approved as the Only Cell Therapy for Blood Cancer Patients Lacking Donor Access Zemcelpro® has gained conditional EC approval, marking a significant advancement for adult patients with hematological malignancies needing stem cell transplantation without suitable donors.

Zemcelpro® Approved as the Only Cell Therapy for Blood Cancer Patients Lacking Donor Access #None #Zemcelpro #ExCellThera #UM171

Zemcelpro®: A Revolutionary Solution for Blood Cancer Patients Without Donors Zemcelpro® is the first authorized cell therapy for blood cancer patients lacking suitable donors. This innovative treatment opens new doors for effective care.

Zemcelpro®: A Revolutionary Solution for Blood Cancer Patients Without Donors #None #Zemcelpro #ExCellThera #UM171

Zemcelpro®: A Landmark Approval for Blood Cancer Treatment in Europe Zemcelpro® receives conditional authorization as the first cell therapy for blood cancer patients lacking suitable donors, promising hope to many in need.

Zemcelpro®: A Landmark Approval for Blood Cancer Treatment in Europe #None #Zemcelpro #ExCellThera #UM171

Zemcelpro® (UM171 Cell Therapy) Achieves Positive CHMP Recommendation for Blood Cancer Treatment Zemcelpro®, a new cell therapy, receives a favorable CHMP opinion. This therapy could enhance donor cell access for blood cancer patients without suitable donors.

Zemcelpro® (UM171 Cell Therapy) Achieves Positive CHMP Recommendation for Blood Cancer Treatment #None #Montreal #ExCellThera #UM171 #Zemcelpro®

Zemcelpro®: A Revolutionary Treatment for Blood Cancer Patients Lacking Donor Cells Zemcelpro® has received positive feedback from the CHMP, potentially transforming blood cancer therapies for patients without appropriate donor cells.

Zemcelpro®: A Revolutionary Treatment for Blood Cancer Patients Lacking Donor Cells #Canada #Montreal #Cell_Therapy #Zemcelpro #ExCellThera

Positive CHMP Opinion for Zemcelpro®: A Breakthrough in Blood Cancer Therapy Zemcelpro® has received a favorable recommendation for the treatment of blood cancer patients lacking suitable donor cells, with the EU decision forthcoming.

Positive CHMP Opinion for Zemcelpro®: A Breakthrough in Blood Cancer Therapy #None #Zemcelpro #ExCellThera #UM171